BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 17572194)

  • 1. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.
    Makarov DV; Trock BJ; Humphreys EB; Mangold LA; Walsh PC; Epstein JI; Partin AW
    Urology; 2007 Jun; 69(6):1095-101. PubMed ID: 17572194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
    Partin AW; Mangold LA; Lamm DM; Walsh PC; Epstein JI; Pearson JD
    Urology; 2001 Dec; 58(6):843-8. PubMed ID: 11744442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.
    Eifler JB; Feng Z; Lin BM; Partin MT; Humphreys EB; Han M; Epstein JI; Walsh PC; Trock BJ; Partin AW
    BJU Int; 2013 Jan; 111(1):22-9. PubMed ID: 22834909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
    BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.
    Huang Y; Isharwal S; Haese A; Chun FK; Makarov DV; Feng Z; Han M; Humphreys E; Epstein JI; Partin AW; Veltri RW
    BJU Int; 2011 May; 107(10):1562-9. PubMed ID: 20875091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
    Partin AW; Kattan MW; Subong EN; Walsh PC; Wojno KJ; Oesterling JE; Scardino PT; Pearson JD
    JAMA; 1997 May; 277(18):1445-51. PubMed ID: 9145716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
    Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
    Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer.
    Narayan P; Gajendran V; Taylor SP; Tewari A; Presti JC; Leidich R; Lo R; Palmer K; Shinohara K; Spaulding JT
    Urology; 1995 Aug; 46(2):205-12. PubMed ID: 7542823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of 2001 Partin tables in Turkey: a multicenter study.
    Eskicorapci SY; Karabulut E; Türkeri L; Baltaci S; Cal C; Toktas G; Akpinar H; Ozer G; Sozen S; Tokuc R; Lekili M; Soylu A; Albayrak S; Sahin H; Alpar R; Ozen H
    Eur Urol; 2005 Feb; 47(2):185-9. PubMed ID: 15661412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new nomogram to predict pathologic outcome following radical prostatectomy.
    Crippa A; Srougi M; Dall'Oglio MF; Antunes AA; Leite KR; Nesrallah LJ; Ortiz V
    Int Braz J Urol; 2006; 32(2):155-64. PubMed ID: 16650292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomograms to predict the pathological stage of clinically localized prostate cancer in Korean men: comparison with western predictive tools using decision curve analysis.
    Jeong CW; Jeong SJ; Hong SK; Lee SB; Ku JH; Byun SS; Jeong H; Kwak C; Kim HH; Lee E; Lee SE
    Int J Urol; 2012 Sep; 19(9):846-52. PubMed ID: 22587373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
    Khan MA; Partin AW; Mangold LA; Epstein JI; Walsh PC
    Urology; 2003 Nov; 62(5):866-71. PubMed ID: 14624910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
    Blute ML; Bergstralh EJ; Partin AW; Walsh PC; Kattan MW; Scardino PT; Montie JE; Pearson JD; Slezak JM; Zincke H
    J Urol; 2000 Nov; 164(5):1591-5. PubMed ID: 11025711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the partin nomogram for prostate cancer in a national sample.
    Yu JB; Makarov DV; Sharma R; Peschel RE; Partin AW; Gross CP
    J Urol; 2010 Jan; 183(1):105-11. PubMed ID: 19913246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer.
    Rayn KN; Bloom JB; Gold SA; Hale GR; Baiocco JA; Mehralivand S; Czarniecki M; Sabarwal VK; Valera V; Wood BJ; Merino MJ; Choyke P; Turkbey B; Pinto PA
    J Urol; 2018 Nov; 200(5):1041-1047. PubMed ID: 29852182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Stop-Shop Whole-Body
    Thalgott M; Düwel C; Rauscher I; Heck MM; Haller B; Gafita A; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2018 Dec; 59(12):1850-1856. PubMed ID: 29794224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are prostate carcinoma clinical stages T1c and T2 similar?
    Billis A; Magna LA; Watanabe IC; Costa MV; Telles GH; Ferreira U
    Int Braz J Urol; 2006; 32(2):165-71. PubMed ID: 16650293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?
    Gupta RT; Brown AF; Silverman RK; Tay KJ; Madden JF; George DJ; Polascik TJ
    AJR Am J Roentgenol; 2016 Jul; 207(1):87-95. PubMed ID: 27064383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.